Optimus Pharma will get nod for Molnupiravir Part III trials, Well being Information, ET HealthWorld


Optimus Pharma gets nod for Molnupiravir Phase III trialsHyderabad: Hyderabad-based Optimus Pharma has acquired approval from the Indian drug regulator, Drugs Controller General of India (DCGI), for conducting Part III medical trials of oral anti-viral drug Molnupiravir on sufferers with delicate to reasonable Covid-19 disease.

The corporate mentioned that the trials will probably be performed on as many as 2500 Covid-19 patients affected by delicate and reasonable signs. The drug will probably be administered for a interval of 5 days to the volunteers.

“As per the medical trial protocols permitted, whole of 2500 topics in each delicate and reasonable Covid-19 will probably be randomised within the research in a 1:1 ratio for Molnupiravir with commonplace supportive care or standalone commonplace supportive care. The remedy period is a most of 5 days and the overall research period will probably be most for 29 days from randomisation,” the corporate mentioned.

Molnupiravir is an experimental anti-viral drug developed for influenza and is now being repurposed for Covid-19.

Observe and join with us on , Facebook, Linkedin

Source link


Please enter your comment!
Please enter your name here